Ziresovir TQT Study Initiated by Shanghai Ark Biopharma
A TQT clinical study evaluating ziresovir's effects on cardiac repolarization has been initiated.
Company
Pharmaceutical intelligence for Shanghai Ark Biopharma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.